natgillin/translations-raw huggingface dataset:
In children over 12 years old with Primary IGFD and in healthy adults there were no apparent differences between males and females in the pharmacokinetics of INCRELEX.
Pri otrocih s primarnim pomanjkanjem IGF, starejših od 12 let, in pri zdravih odraslih se farmakokinetika zdravila INCRELEX med osebami moškega in ženskega spola ni pomembneje razlikovala.
In children primed at toddler age, the persistence of the immune response was evaluated by rSBA and hSBA in studies MenACWY-TT-048 and MenACWY-TT-032, up to 4 years after priming in study MenACWY-TT-039 (Table 5) and up to 5 years after priming in study MenACWY-TT-027 (Table 6) respectively.
Pri otrocih, ki so prejeli osnovno cepljenje kot malčki, so trajanje imunskega odziva ocenili z rSBA in hSBA v študijah MenACWY-TT-048 in MenACWY-TT-032, do 4 leta po osnovnem cepljenju v študiji MenACWY-TT-039 (preglednica 5) in do 5 let po osnovnem cepljenju v študiji MenACWY- TT-027 (preglednica 6).
In children the most common side effects (seen in more than 1 patient in 10) are vomiting, cough and nasal congestion (a blocked nose).
Pri otrocih so najpogostejši neželeni učinki (opaženi pri več kot 1 bolniku od 10) bruhanje, kašelj in kongestija nosne sluznice (zamašen nos).
In children under 18 years of age, there is a possible association between ASA and Reye’s syndrome.
Pri otrocih, mlajših od 18 let, je možna povezava med ASA in Reyevim sindromom.
In children under 18 years of age, there is a possible association between ASA and Reye’s syndrome.
Pri otrocih, mlajših od 18 let, obstaja možna povezanost med ASA in Reyevim sindromom.
In children up to 17 years of age, the recommended dose of Busulfan Fresenius Kabi varies between 0.8 and 1.2 mg per kilogram depending on the weight of the child.
Pri otrocih do 17. leta starosti je priporočeni odmerek zdravila Busulfan Fresenius Kabi odvisen od njihove telesne mase, in sicer znaša od 0,8 do 1,2 mg/kg.
In children weighing at least 40 kg, Simponi is used for the treatment of polyarticular juvenile idiopathic arthritis.
Pri otrocih, ki tehtajo najmanj 40 kg, se zdravilo Simponi uporablja za zdravljenje poliartikularnega juvenilnega idiopatskega artritisa.
In children whose mothers took medicines like Viread (NRTIs) during pregnancy, the benefit from the protection against the virus outweighed the risk of side effects.
Pri otrocih, katerih matere so med nosečnostjo jemale zdravila, kot je zdravilo Viread (nukleozidne zaviralce reverzne transkriptaze (NRTI, nucleoside reverse transcriptase inhibitors), je korist zaradi zaščite proti virusu odtehtala tveganje zaradi neželenih učinkov.
In children whose mothers took NRTIs during pregnancy, the benefit from the protection against HIV outweighed the risk of side effects.
Pri otrocih, katerih matere so med nosečnostjo jemale nukleozidne zaviralce reverzne transkriptaze (NRTI-nucleoside reverse transcriptase inhibitors), je korist zaradi zaščite proti HIV odtehtala tveganje zaradi neželenih učinkov.
In children whose mothers took NRTIs during pregnancy, the benefit from the protection against HIV outweighed the risk of side effects.
Pri otrocih, katerih matere so med nosečnostjo jemalenukleozidne zaviralce reverzne transkriptaze (NRTI, nucleoside reverse transcriptase inhibitors), je korist zaradi zaščite proti HIV odtehtala tveganje zaradi neželenih učinkov.
In children whose mothers took NRTIs during pregnancy, the benefit from the protection against HIVoutweighed the risk of side effects.
Pri otrocih, katerih matere so med nosečnostjo jemalenukleozidne zaviralce reverzne transkriptaze (NRTI, nucleoside reverse transcriptase inhibitors), je korist zaradi zaščite proti HIV odtehtala tveganje zaradi neželenih učinkov.
In children with chronic hepatitis C, the effectiveness of 48 weeks of treatment with Pegasys and ribavirin was examined in 55 children in one main study.
Pri otrocih s kroničnim hepatitisom C so v eni glavni študiji primerjali učinkovitost 48-tedenskega zdravljenja z zdravilom Pegasys in ribavirinom pri 55 otrocih.
In children with chronic ITP, Revolade was compared with placebo in one main study involving a total of 92 children between 1 and 17 years of age who had previously received treatment for ITP.
Pri otrocih s kronično imunsko trombocitopenično purpuro so zdravilo Revolade primerjali s placebom v eni glavni študiji, ki je vključevala skupno 92 otrok, starih od enega do sedemnajst let, ki so bili predhodno zdravljeni zaradi imunske trombocitopenične purpure.
In children with complicated skin or soft tissue infections aged 7 to 17 years, Cubicin is given as an infusion lasting 30 minutes, whereas in children aged 1 to 6 years the infusion should last 60 minutes.
Pri otrocih z zapletenimi oblikami okužbe kože ali mehkih tkiv, starih od sedem do 17 let, se zdravilo daje s 30-minutnim infundiranjem, medtem ko mora pri otrocih, starih od enega do šest let, to trajati 60 minut.
In children with diabetes, blood glucose monitoring should be increased.
Pri otrocih z diabetesom je treba povečati nadzor glukoze v krvi.
In children with growth hormone deficiency:
Otroci s pomanjkanjem rastnega hormona:
In children with ITP, the daily recommended dose is 25 mg for children aged 1 to 5 years, and 50 mg for children aged 6 to 17 years, except in patients of East Asian descent (such as Japanese, Chinese, Taiwanese or Korean) where it should be 25 mg once a day.
Pri otrocih z imunsko trombocitopenično purpuro, starih od enega do pet let, je priporočeni dnevni odmerek 25 mg, pri otrocih, starih od šest do sedemnajst let, pa 50 mg, razen pri bolnikih vzhodnoazijskega porekla (kot so Japonci, Kitajci, Tajvanci ali Korejci), pri katerih znaša 25 mg enkrat na dan.
In children with PAH aged 1 year and older, the recommended starting and maintenance dose is 2 mg per kilogram body weight twice a day.
Pri otrocih s PAH, starejših od enega leta, je priporočeni začetni in vzdrževalni odmerek 2 mg na kilogram telesne mase dvakrat na dan.
In children with PAH, the dose to use is calculated based on body weight, and usually starts at 2 mg per kilogram body weight twice a day.
Pri otrocih s pljučno arterijsko hipertenzijo se odmerek izračuna glede na telesno maso, pri čemer se zdravljenje običajno začne z 2 mg na kilogram telesne mase dvakrat na dan.
In children with ulcerative colitis, 73% of patients responded to treatment at week eight (44 out of 60); in psoriasis, Remicade led to a greater improvement in symptoms than placebo.
Pri otrocih z ulceroznim kolitisom se je po osmem tednu na zdravljenje odzvalo 73 % (44 od 60) bolnikov; pri psoriazi je zdravilo Remicade privedlo do večjega izboljšanja simptomov kot placebo.
In children, accidental ingestion should be regarded as serious.
Posledice pri otrocih, ki so po nesreči zaužili to zdravilo, obravnavajte zelo resno.
In children, administration of tablets delivered higher plasma lamivudine AUC∞ and Cmax than oral solution.
U detí sa pri podávaní tabliet dosiahli vyššie hodnoty AUC∞ a Cmax lamivudínu v plazme ako pri podávaní perorálneho roztoku.
In children, four weeks after the final injection, 99% to 100 % of children who received both doses of Ixiaro had developed protective levels of antibodies.
Pri otrocih so se štiri tedne po zadnjem odmerku zaščitne ravni protiteles pojavile pri 99 do 100 % otrok, ki so bili cepljeni z obema odmerkoma.
In children, its effectiveness was comparable to that of the comparators, and to the effectiveness seen in adults.
Pri otrocih je bila učinkovitost zdravila Invanz primerljiva z učinkovitostjo primerjalnih zdravil in učinkovitostjo pri odraslih bolnikih.
In children, maintenance treatment should be suspended after 12 months, to assess whether the need for continued treatment still exists.
Pri otrocih je treba vzdrževalno zdravljenje po 12 mesecih prekiniti in oceniti potrebo po nadaljnjem zdravljenju.
In children, the dose depends on body weight and ranges from 100 mg twice a day to 200 mg twice a day.
Pri otrocih je odmerek odvisen od telesne mase in znaša od 100 mg dvakrat na dan do 200 mg dvakrat na dan.
In choroidal neovascularisation due to pathologic myopia, on average in the first 3 months of treatment, patients given Lucentis could see around 8-9 letters more than those receiving verteporfin PDT.
Pri horoidalni neovaskularizaciji zaradi bolezenske kratkovidnosti so bolniki, ki so prejemali zdravilo Lucentis, v povprečju v prvih treh mesecih zdravljenja videli približno 8 do 9 črk več kot tisti, ki so prejemali PDT z verteporfinom.
In chronic hepatitis B in adults, two studies have been carried out comparing Pegasys with lamivudine (another antiviral medicine) in 820 ‘HBeAg-positive’ patients (infected with the common type of the hepatitis B virus) and in 552 ‘HBeAg-negative’ patients (infected with a virus that has mutated [changed], leading to a form of chronic hepatitis B that is more difficult to treat).
Pri kroničnem hepatitisu B pri odraslih sta bili izvedeni dve študiji, v kateri so primerjali zdravilo Pegasys z lamivudinom (drugim protivirusnim zdravilom) pri 820 bolnikih, ki so bili „HBeAg pozitivni“ (okuženi z običajno vrsto virusa hepatitisa B), ter pri 552 bolnikih, ki so bili „HBeAg negativni“ (okuženi z virusom, ki je mutiral [se spremenil], kar je pripeljalo do oblike hepatitisa B, ki jo je težje zdraviti).
In chronic hepatitis B or C patients, peginterferon alfa-2a serum concentrations accumulate 2 to 3 fold after 6 to 8 weeks of once weekly dosing compared to single dose values.
Pri bolnikih s kroničnim hepatitisom B ali C prihaja po 6 do 8 tednih zdravljenja do 2- do 3-kratne kumulacije serumskih koncentracij peginterferona alfa-2a po odmerjanju enkrat na teden v primerjavi z vrednostmi enkratnega odmerka.
In chronic hepatitis B, Pegasys was more effective than lamivudine in both HBeAg-positive and negative patients.
Pri kroničnem hepatitisu B je bilo zdravilo Pegasys učinkovitejše od lamivudina pri HBeAg pozitivnih in tudi HBeAg negativnih bolnikih.
In chronic hepatitis B, unlike chronic hepatitis C, disease exacerbations during therapy are not uncommon and are characterised by transient and potentially significant increases in serum ALT.
Pri kroničnem hepatitisu B, v nasprotju s kroničnim hepatitisom C, poslabšanja bolezni med zdravljenjem niso redka in so opisana kot prehodna in potencialno pomembna zvišanja ALT v serumu.
In chronic hepatitis C clinical trials with adult patients, isolated increases in ALT (≥ 10x ULN, or ≥ 2x BL for patients with a BL ALT ≥ 10x ULN) which resolved without dose-modification were observed in 8 of 451 patients treated with combination therapy.
Med kliničnimi preskušanji kroničnega hepatitisa C pri odraslih bolnikih, so pri 8 od 451 bolnikov, ki so prejemali kombinirano zdravljenje, opazili posamezne primere zvišanja ALT (≥ 10-kratna zgornja referenčna vrednost (ULN - Upper Limit of the Normal Range) ali ≥ 2-kratna BL pri bolnikih z BL ALT ≥ 10-kratna zgornja referenčna vrednost (ULN)), ki pa so se normalizirala brez prilagajanja odmerkov.
In chronic hepatitis C in adults, Pegasys has been studied on its own in three studies involving a total of 1,441 patients, and in combination with ribavirin in one study involving 1,149 patients.
Pri kroničnem hepatitisu C so zdravilo Pegasys v samostojni uporabi proučevali v treh študijah, v katere je bilo vključenih 1 441 bolnikov, v kombinaciji z ribavirinom pa v eni študiji, ki je vključevala 1 149 bolnikov.
In chronic hepatitis C in adults, Pegasys on its own was more effective than interferon alfa-2a.
Pri kroničnem hepatitisu C pri odraslih je bilo zdravilo Pegasys učinkovitejše od interferona alfa-2a.
In chronic iron overload due to blood transfusions, Exjade was investigated in one main study comparing Exjade with deferoxamine in 591 patients with beta thalassaemia major.
Pri kronični preobremenitvi z železom zaradi transfuzij krvi so v eni glavni študiji zdravilo Exjade primerjali z deferoksaminom pri 591 bolnikih z beta talasemijo major.
In Chronic Kidney Disease (CKD) patients receiving dialysis who were administered cinacalcet, approximately 30% of patients had at least one serum calcium value less than 7.5 mg/dl (1.9 mmol/l).
Pri bolnikih s kronično boleznijo ledvic, ki so se zdravili z dializo in so prejemali cinakalcet, je imelo približno 30% bolnikov vsaj eno vrednost kalcija v serumu manj kot 7,5 mg/dl (1,9 mmol/l).
In chronic lymphocytic leukaemia and Waldenström’s macroglobulinaemia, the recommended dose is 3 capsules once a day, whereas in mantle cell lymphoma it is 4 capsules once a day.
Priporočeni odmerek zdravila za zdravljenje kronične limfocitne levkemije in Waldenströmove makroglobulinemije znaša tri kapsule enkrat na dan, za zdravljenje limfoma plaščnih celic pa štiri kapsule enkrat na dan.
In chronic renal failure patients the rate of increase in haemoglobin should be approximately 1 g/dl (0.62 mmol/l) per month and should not exceed 2 g/dl (1.25 mmol/l) per month to minimise risks of an increase in hypertension.
Pri bolnikih s kroničnim ledvičnim odpovedovanjem mora biti stopnja zvišanja hemoglobina približno 1 g/dl (0,62 mmol/l) na mesec in ne sme presegati 2 g/dl (1,25 mmol/l) na mesec, da se zmanjša tveganje zvišanja pri hipertenziji.
In chronic renal failure patients, correction for anaemia may lead to increased appetite, and potassium and protein intake.
Pri bolnikih s kronično ledvično okvaro je popravek anemije imel za posledico povečan apetit in povečan vnos kalija in proteinov.
In chronic renal failure patients: there may be a moderate dose-dependent rise in the platelet count within the normal range during treatment with NeoRecormon, especially after intravenous administration.
Pri bolnikih s kronično ledvično boleznijo se lahko med zdravljenjem z zdravilom NeoRecormon, zlasti po intravenskem dajanju zmerno, odvisno od velikosti odmerka, poveča število trombocitov, ki pa ostane znotraj normalnega območja.
In CKD 5D patients, the primary evaluation of safety is based on the integrated analysis of data from 4 studies involving 557 CKD 5D patients treated with Fexeric for up to 1 year.
Pri bolnikih s KLB 5D je primarna ocena varnosti temeljila na integrirani analizi podatkov iz 4 študij, ki so vključile 557 bolnikov s KLB 5D, ki so se največ eno leto zdravili z zdravilom Fexeric.
In CKD patients receiving dialysis who were administered Mimpara, approximately 30% of patients had at least one serum calcium value less than 7.5 mg/dl (1.9 mmol/l).
Pri bolnikih s kronično boleznijo ledvic, ki so se zdravili z dializo in so prejemali zdravilo Mimpara, je imelo približno 30 % bolnikov vsaj eno vrednost kalcija v serumu manj kot 7,5 mg/dl (1,9 mmol/l).
In CKD patients, the maximum average daily dose studied was 14.4 grams of sevelamer carbonate in a single daily dose.
Pri bolnikih s KBL je bil največji preučen povprečni dnevni odmerek 14,4 grama sevelamerijev karbonata v obliki enega dnevnega odmerka.
In CLARITY, there was an overall increase in bleeding in the clopidogrel + ASA group (17.4%) vs. the placebo + ASA group (12.9%).
V študiji CLARITY je v skupini bolnikov, ki so se zdravili s klopidogrelom in ASA, prišlo do splošnega povečanja krvavitev (17,4%%) v primerjavi s skupino, ki je jemala placebo in ASA (12,9%%).
In class III or IV PAH that was either primary or caused by scleroderma, the two studies showed that patients treated with Stayveer were able to walk further than patients treated with placebo after 16 weeks (44 metres further in the larger study), but there were too few patients with class IV disease to support the use of the medicine in this group.
Dve študiji pri bolnikih s pljučno arterijsko hipertenzijo razreda III ali IV, ki je bila bodisi primarna bodisi posledica skleroderme, sta pokazali, da so po 16 tednih bolniki, zdravljeni z zdravilom Stayveer, lahko prehodili daljšo razdaljo kot bolniki, zdravljeni s placebom (44 metrov več v obsežnejši študiji), vendar pa je bilo v študijo vključenih premalo bolnikov s pljučno arterijsko hipertenzijo razreda IV, da bi lahko zagovarjali uporabo zdravila pri tej skupini.
In class III or IV PAH that was either primary or caused by scleroderma, the two studies showed that patients treated with Tracleer were able to walk further than patients treated with placebo after 16 weeks (44 metres further in the larger study), but there were too few patients with class IV disease to support the use of the medicine in this group.
Pri PAH III. ali IV. funkcijskega razreda, ki je bila primarna ali posledica skleroderme, sta dve študiji pokazali, da so bolniki, zdravljeni z zdravilom Tracleer, po 16 tednih zdravljenja lahko prehodili večjo razdaljo kot bolniki, ki so prejemali placebo (44 metrov dlje v obširnejši študiji), vendar je bilo vključenih premalo bolnikov z boleznijo IV. funkcijskega razreda, da bi lahko podprli uporabo zdravila v tej skupini.
In clincial trials ophthalmologic reactions, including uveitis, iridocyclitis and iritis, have been reported in patients treated with dabrafenib as monotherapy and in combination with trametinib.
V kliničnih študijah so pri bolnikih, ki so prejemali dabrafenib v monoterapiji ali v kombinaciji s trametinibom, opisovali oftalmološke reakcije, vključno z uveitisom, iridociklitisom in iritisom.
In clincial trials uveitis and iridocyclitis have also been reported in patients treated with trametinib in combination with dabrafenib.
V kliničnih preskušanjih so pri bolnikih, ki so prejemali trametinib v kombinaciji z dabrafenibom, poročali tudi o uveitisu in iridociklitisu.
In clinical drug-drug interaction studies in healthy subjects, delamanid was administered alone (100 mg twice daily) and with tenofovir (300 mg daily) or lopinavir/ritonavir (400/100 mg daily) for 14 days and with efavirenz for 10 days (600 mg daily).
V kliničnih študijah medsebojnega delovanja zdravil pri zdravih osebah so 14 dni dajali samo delamanid (100 mg dvakrat na dan) in skupaj s tenofovirjem (300 mg na dan) ali lopinavirjem/ritonavirjem (400/100 mg na dan) in z efavirenzom 10 dni (600 mg na dan).
In clinical interaction studies, amlodipine did not affect the pharmacokinetics of atorvastatin, digoxin, warfarin or  ciclosporin.
V kliničnih študijah medsebojnega delovanja amlodipin ni vplival na farmakokinetiko atorvastatina, digoksina,  varfarina ali ciklosporina.
In clinical interaction studies, amlodipine did not affect the pharmacokinetics of atorvastatin, digoxin, warfarin or ciclosporin.
V kliničnih študijah medsebojnega delovanja amlodipin ni vplival na farmakokinetiko atorvastatina, digoksina, varfarina in ciklosporina.
In clinical pharmacology studies, healthy subjects received rivaroxaban 20 mg once daily, dabigatran 150 mg twice daily, or apixaban 5 mg twice daily, followed by a single dose of edoxaban 60 mg on Day 4.
V kliničnofarmakoloških študijah so zdravi preiskovanci prejemali rivaroksaban 20 mg enkrat na dan, dabigatran 150 mg dvakrat na dan ali apiksaban 5 mg dvakrat na dan, ki mu je 4. dne sledil enkraten odmerek edoksabana 60 mg.
In clinical pharmacology studies, intravenous insulin glargine and human insulin have been shown to be equipotent when given at the same doses.
Klinično farmakološke študije so dokazale, da sta intravensko uporabljena insulin glargin in humani insulin v enakih odmerkih ekvipotentna.
In clinical pharmacology studies, the half-life of naloxegol at therapeutic dose ranged from 6–11 hours.
V kliničnih farmakoloških študijah je bil razpolovni čas naloksegola v terapevtskih odmerkih od 6 do 11 ur.
In clinical pharmacology studies, the potential for tadalafil (10 and 20 mg) to augment the hypotensive effects of antihypertensive medicinal products was examined.
V študijah klinične farmakologije so preiskovali zmožnost tadalafila (10 in 20 mg), da okrepi hipotenzivne učinke antihipertenzivnih zdravil.
In clinical pharmacology trials in adults, co-administration with alcohol did not increase the alcohol- induced impairment in performance or increase in sleepiness.
V kliničnih farmakoloških preskušanjih pri odraslih sočasna uporaba zdravila z alkoholom ni okrepila škodljivega vpliva alkohola na psihomotorične sposobnosti ali povečala zaspanosti pri bolnikih.
In clinical pharmacology trials, co-administration with alcohol did not increase the alcohol-induced impairment in performance or increase in sleepiness.
V kliničnofarmakoloških preskušanjih sočasna uporaba desloratadina z alkoholom ni povečala z alkoholom povezanega poslabšanja zmogljivosti in ni povečala zaspanosti.
In clinical phase III, at total of 384 patients were treated with Ameluz.
V klinični fazi III je bilo z zdravilom Ameluz skupaj zdravljenih 384 bolnikov.
In clinical practice, treatment will be based on the need to control serum phosphorus levels, though patients who respond to Velphoro therapy usually achieve optimal serum phosphorus levels at doses of 1,500 mg-2,000 mg iron per day (3 to 4 tablets).
V klinični praksi bo zdravljenje odvisno od potrebe po nadzoru ravni fosforja v serumu, čeprav bolniki, ki se odzivajo na terapijo z zdravilom Velphoro, običajno dosežejo optimalne ravni fosforja v serumu pri odmerkih od 1500 mg do 2000 mg železa na dan (3 do 4 tablete).
In clinical practice, whole blood trough levels have generally been in the range of 5-20 ng/mL in kidney transplant patients in the early post- transplant period, and 5-15 ng/mL during subsequent maintenance therapy.
V klinični praksi so bile najmanjše koncentracije v polni krvi v zgodnjem obdobju po presaditvi pri prejemnikih ledvic na splošno v območju od 5 do 20 ng/mL in v območju od 5 do 15 ng/mL pri poznejšem vzdrževalnem zdravljenju.
In clinical RA studies and post-marketing experience, rare cases of opportunistic infections have been observed and included fungal, mycobacterial, bacterial, and viral pathogens.
V kliničnih študijah RA in izkušnjah po začetku trženja so zabeležili redke primere oportunističnih okužb, ki so vključevale glivične, mikobakterijske, bakterijske in virusne patogene.
In clinical registrational studies the incidence of cholecystitis was 0.5%.
V kliničnih registracijskih študijah je pojavnost holecistitisa znašala 0,5 %.
In clinical studies 1468 patients received Plegridy for up to 177 weeks (overall exposure equivalent to 1932 person-years).
V kliničnih študijah je 1.468 bolnikov zdravilo Plegridy prejemalo do 177 tednov (celokupna izpostavljenost ustreza 1.932 oseb-let).
In clinical studies 2.5 % (4/161), 5.1 % (17/332) and 4.0% (10/249) of the patients on brivaracetam 50 mg/day, 100 mg/day and 200 mg/day respectively became seizure free during the 12-week treatment period compared with 0.5 % (2/418) on placebo.
2,5 % (4/161), 5,1 % (17/332) in 4,0 % (10/249) bolnikov, ki so prejemali brivaracetam v odmerkih po 50 mg/dan, 100 mg/dan in 200 mg/dan, napadi odpravljeni med 12-tedenskim zdravljenjem, v primerjavi z 0,5 % (2/418) pri bolnikih, ki so prejemali placebo.
In clinical studies 24% of patients treated with MIRCERA were ageg 65 to 74 years, while 20% were ageg 75 years and over.
V kliničnih preskušanjih je bilo 24 % bolnikov, zdravljenih z zdravilom MIRCERA, starih od 65 do 74 let, 20 % pa 75 let in več.
In clinical studies 99.6% to 100% who received Gardasil 9 became seropositive for antibodies against all 9 vaccine types by Month 7 across all groups tested.
V kliničnih študijah je v vseh testiranih skupinah do 7. meseca od 99,6 % do 100 % oseb, ki so prejele cepivo Gardasil 9, postalo seropozitivnih za protitelesa proti vsem 9 tipom v cepivu.
In clinical studies and post-marketing experience, rare cases of opportunistic infections have been observed and included fungal, mycobacterial, bacterial, and viral pathogens.
V kliničnih študijah in izkušnjah po začetku trženja so zabeležili redke primere oportunističnih okužb, ki so vključevale glivične, mikobakterijske, bakterijske in virusne patogene.